https://doi.org/10.1016/s0140-6736(25)00860-8
C
Chang Liu
Claim or correct this author profile
Claim this profile or suggest corrections to the name, affiliation, bio, photo, or paper titles. Approved changes appear as verified CitedEvidence overlays.
14
Papers
286
Citations
6
h-index
5
i10-index
Chang Liu is an academic researcher from Novartis (Switzerland). The author has contributed to research in topics: CAR-T cell therapy research & Cancer Immunotherapy and Biomarkers & Lung Cancer Diagnosis and Treatment. The author has an h-index of 6, co-authored 12 publications.
ORCID: 0000-0001-9388-4180Papers by this author
worksClaudin-18 isoform 2-specific CAR T-cell therapy (satri-cel) versus treatment of physician's choice for previously treated advanced gastric or gastro-oesophageal junction cancer (CT041-ST-01): a randomised, open-label, phase 2 trial
2025 · The Lancet · 74 citations
The AKR1C1–CYP1B1–cAMP signaling axis controls tumorigenicity and ferroptosis susceptibility of extrahepatic cholangiocarcinoma
2024 · Cell Death and Differentiation · 18 citations
https://doi.org/10.1038/s41418-024-01407-1
A bispecific antibody–drug conjugate targeting EGFR and HER3 in metastatic esophageal squamous cell carcinoma: a phase 1b trial
2025 · Nature Medicine · 8 citations
https://doi.org/10.1038/s41591-025-03792-7
An integrated prognosis prediction model based on real-word clinical characteristics for immunotherapy in advanced esophageal squamous cell carcinoma
2025 · Cancer Immunology Immunotherapy · 5 citations
https://doi.org/10.1007/s00262-025-03963-y
Fusarium Fungemia of T-lymphoblastic Lymphoma after HSCT: a Case Report and Review of the Literature
2025 · Clinical Laboratory · 2 citations
https://doi.org/10.7754/clin.lab.2024.240836
Research topics
topicsChat about Author
Papers
Chat
Click to start Chat